Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults

Acta Tropica

Volumn 81, Issue 2, 2002, Pages 167-173

  Rendi Wagner, Pamela ^a   Noedl, Harald ^a   Wernsdorfer, Walther H ^a,b   Wiedermann, Gerhard ^a   Mikolasek, Andrea ^a   Kollaritsch, Herwig ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Adverse effects; Healthy adults; Malaria; Mefloquine; Stand by; Therapy

Indexed keywords

BILIRUBIN; CALCIUM; CHLORINE; DIMENHYDRINATE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; MEFLOQUINE; SODIUM;

DRUG PRESCRIBING; MALARIA;

ADULT; ARTICLE; BED REST; BIOCHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MONITORING; FEMALE; HEADACHE; HEMATOLOGY; HUMAN; MALARIA; MALE; MORBIDITY; NAUSEA; NORMAL HUMAN; SEX DIFFERENCE; SYMPTOM; VERTIGO;

ADULT; ANTIMALARIALS; FEMALE; HEADACHE; HUMANS; MALE; MEFLOQUINE; NAUSEA; TIME FACTORS; VERTIGO;

EID: 0036153103     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-706X(01)00210-8     Document Type: Article

References (28)

1. An integrated assessment of the clinical safety of artemether-lumefantrine: A new oral fixed-dose combination antimalarial drug
2. Comparison of adverse effects associated with use of mefloquine and combination of chloroquine and proguanil as antimalarial prophylaxis: Postal and telephone survey of travellers
3. Mefloquine to prevent malaria: A systematic review of trials
4. The antimalarial mefloquine inhibits ATP-sensitive K-channels
5. Mefloquine concentration profiles during prophylaxis dose regimens
6. Dangers of anti-malarial standby-treatment
7. Malarone (atovaquone proguanil hydrochloride): A review of its clinical development for treatment of malaria
8. Efficay and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand
9. Mefloquine for multi-drug resistant malaria
10. Inhibition of volume-regulated and calcium-activated chloride channels by the antimalarial mefloquine
11. Pharmacokinetics of mefloquine when given as a single and two divided-dose regimens
12. Mefloquine-resistant falciparum malaria on the Thai-Burmese border
13. Reported side effects to chloroquine plus proguanil, and mefloquine as chemoprophylaxis against malaria in Danish travelers
14. CNS adverse events associated with antimalarial agents facts or fiction?
15. Neuropsychiatric problems in 2500 long-term young travelers to the tropics
16. Atovaquone and proguanil for Plasmodium falciparum malaria
17. Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: Comparing a retrospective and a prospective study
18. Mefloquine for malaria chemoprophylaxis 1992-1998: A review
19. Stand-by treatment of malaria in travellers: A review
20. Mefloquine tolerability during chemoprophylaxis: Focus on adverse event assessments, stereochemistry and compliance
21. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting East Africa
22. Mefloquine treatment of acute falciparum malaria: A prospective study of nonserious adverse effects in 3673 patients
23. Neuro-psychiatric effects of anti-malarials
24. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multi-drug-resistent Plasmodium falciparum malaria
25. Artemether-lumefantrine for the treatment of multi-drug-resistant falciparum malaria
26. Neuropsychiatric side effects after the use of mefloquine
27. Advances in malaria chemotherapy. Report of a WHO scientific group